Ivy22 Apr 2018 03:15
Yeah winning the Grand Challenge and even just even working with the team members we have can only take us up to a new level, even the SCIB2 Combo will be followed with great interest. I think in CRUK we are comportably placed to put our name in the highlights and build that shareholder base that still seems low to other companies.
The AIM market has changed so much in Biotech, whether it be treatments, diagnostics or services. A question i have wanted to ask is with so many new companies in the sector, rather spoilt for choice, can we tell how much investment has and is increasing in the sector. Seems like it is growing enormously, driven by investors looking for multi baggers whilst understanding the risks along the way. As you say still in 2018 we haven"t come close to being fully evaluated , not so much validated but valued.
It would appear that we all are very aware of the enormous potential here, the inflection points that will come aand i have noticed an increased appetite for buyers increasing all the time. Worth adding too we are all aware of the risk associated with this market, the journey to Approval, Commercialisation is a long one, nd whilst some people still question the BODs ability on the business side all the trials to me are being designed for early results and the quest to enter into all the trials has been supported by important collaborations and partnerships to give us the very best chance to succeed. Some people still have a gripe over RGS period in charge, i would prefer it if they just saw how far as a company we have progressed in the past year.
They say many LTHS are a result of short term trades that went wrong i.e after we were the highest share to rise back in 2013, seems so long ago, but our recent excursions to breaking 20p have filled me with a lot of confidence going forward. The fact we are funded to the tune of �11m at this stage of or development is very key, whilst the same people still have doubts as to the BODs ability, there is no doubt as to our track record in dispersing company funds to hopefully achieve solid returns to shareholders eventually, and to that effect i do not think we will have that long to wait in seeing the SP return to levels we were happy to see and so close to reaching our averages, The opportunity to buy at 12p again should see many an average lowered. GL All, we are singing from the same song sheets as we have for some time now.
Sign In
Follow the stocks
